European Medicines Agency publishes interim fee advice for bluetongue-vaccine manufacturers

View source ↗

Summary

EMA released interim fee advice for manufacturers of bluetongue vaccines, outlining anticipated fees and charging framework during the interim period.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bluetongue Disease